Arcus Biosciences, Inc. (RCUS)

29.21 -4.51% (-1.38)

Over 5Y: -0.8%

2026-08-28
20 40
2021 2022 2023 2024 2025 2026

Financials Quarterly

Q3 '25 — Revenue: 26M Q3 '25 — Operating Cash Flow: -97M Q3 '25 — Free Cash Flow: -97M Q3 '25 — Net Income: -135M Q4 '25 — Revenue: 33M Q4 '25 — Operating Cash Flow: -120M Q4 '25 — Free Cash Flow: -121M Q4 '25 — Net Income: -106M Q1 '26 — Revenue: 17M Q1 '26 — Operating Cash Flow: -138M Q1 '26 — Free Cash Flow: -138M Q1 '26 — Net Income: -128M Q2 '26 — Revenue: 41M Q2 '26 — Operating Cash Flow: -119M Q2 '26 — Free Cash Flow: -119M Q2 '26 — Net Income: -91M -120M -80M -40M 0 40M 80M
Q3 '25 Q4 '25 Q1 '26 Q2 '26
Revenue Operating Cash Flow Free Cash Flow Net Income

Figures as at 2026-06-30, reported in USD. The newest fact in the filings is dated 2026-06-30, 61 days ago. Nothing on this page is advice.

How it scores

Five questions, each answered by the measures under it. Every figure is the company's own; the bar beside it is where that figure sits among the companies read here — the top fifth, the bottom fifth, or somewhere between. Not among all listed companies, and for a valuation multiple the low end is the good end.

Quality

How much of the revenue is really kept — and what did it take to earn it?

0.6
SBC / sales 53.8%
OE margin -459.8%
Oper. margin -415.4%
Accruals 1.5%
EBITDA margin -406.8%
FCF margin -406.0%
OCF margin -405.1%
Profit margin -393.2%
ROA -49.8%
ROCE -66.9%
ROE -99.1%
Gross margin —
OCF / EBIT —
ROIC —

4 of 17 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Valuation

What does the price ask for what the company earns, owns and pays out?

0.5
Div. yield —
EV/EBIT —
EV/GP —
EV/OE —
EV/Sales —
FCF yield —
Fwd P/E —
P/B —
P/C —
P/E —
PEG —

0 of 12 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Durability

How predictable is the revenue, and how much of it is already committed?

4.5
RPO / sales 2.2×
RPO growth -51.0%
Segment HHI —

3 of 7 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Resilience

Can the balance sheet absorb a bad year?

6.5
ND/EBITDA —
Interest cover -40.5×
Cash / Debt 7.0×
Debt payback 0.0 yr
Quick ratio 3.8×
Debt / Eq 0.22×
Cash runway 1.3 yr
F-score 0.0 pts
Payout —

3 of 12 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Growth

Is the business getting bigger, and is it getting more profitable?

1.0
Sales CAGR 4Y -10.4%
Sales/sh Y/Y -62.5%
Sales Q/Q -74.4%
Shares change +19.2%
Div. growth —
EBIT CAGR —
EBIT Y/Y —
EPS CAGR 4Y —
EPS Y/Y —
EPS next Y —

4 of 13 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

A measure absent from a block could not be computed from this company's filings. It is left out rather than scored as though it were bad, and the dimension is averaged over what remains. A score is measured against a fixed scale this model states; the bar is measured against the other companies, so the two can disagree — and where they do, that disagreement is the more interesting figure.